Country
United States
Cancer incidence and mortality for United States as published by the source registry: per site group, per year and sex, with age-standardized rates where the source provides them. Population statistics describe groups, never individuals.
- ISO 3166-1
- USA · US
- WHO region
- WHO Region of the Americas
- Population
- not seeded — CancerIndex shows only rates and counts published by the source
- Years covered
- 1999–2024
- Cancer entities
- 36
- Estimate types
- observed
Summary
2003 · Male · all ages
Totals across all cancer sites are shown only when the source publishes an all-sites row. Otherwise the per-site figures below stand on their own; CancerIndex never sums site groups (definitions overlap between sources).
- Deathshighest site group:Malignant Lung Neoplasm89,906countcdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- New caseshighest site group:Malignant Prostate Neoplasm205,033countcdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- Mortality rate (age-standardized)highest site group:Malignant Lung Neoplasm72per 100,000cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
- Incidence rate (age-standardized)highest site group:Malignant Prostate Neoplasm158.3per 100,000cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
No all-sites total in source for this scope — per-site figures below; no national total is computed.
Top cancers
By deaths
2003 · Male · all ages · 26 site groups
| # | Cancer | Deaths (count) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Lung NeoplasmCancer | 89,906 | — | observed | #1 of 26 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 2 | Malignant Prostate NeoplasmCancer | 29,554 | — | observed | #2 of 26 | USCS "Prostate" (ICD-10 C61; ICD-O-3 C619) | cdc-uscsObserved |
| 3 | Malignant Colon NeoplasmCancer | 23,250 | — | observed | #3 of 26 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 4 | Malignant Pancreatic NeoplasmCancer | 15,060 | — | observed | #4 of 26 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 5 | LeukemiaCancer Family | 12,104 | — | observed | #5 of 26 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 6 | Non-Hodgkin LymphomaHematologic Malignancy | 11,399 | — | observed | #6 of 26 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 7 | Malignant Esophageal NeoplasmCancer | 9,921 | — | observed | #7 of 26 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 8 | Malignant Liver NeoplasmCancer | 9,482 | — | observed | #8 of 26 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 9 | Malignant Bladder NeoplasmCancer | 8,576 | — | observed | #9 of 26 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 10 | Malignant Kidney NeoplasmCancer | 7,667 | — | observed | #10 of 26 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 11 | Malignant Central Nervous System NeoplasmCancer | 7,122 | — | observed | #11 of 26 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 12 | Malignant Gastric NeoplasmCancer | 7,055 | — | observed | #12 of 26 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 13 | Multiple MyelomaHematologic Malignancy | 5,588 | — | observed | #13 of 26 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 14 | Cutaneous MelanomaCancer | 4,963 | — | observed | #14 of 26 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 15 | Malignant Rectal NeoplasmCancer | 4,740 | — | observed | #15 of 26 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 16 | Malignant Laryngeal NeoplasmCancer | 3,020 | — | observed | #16 of 26 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 17 | Malignant MesotheliomaCancer Family | 2,007 | — | observed | #17 of 26 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 18 | Hodgkin LymphomaHematologic Malignancy | 725 | — | observed | #18 of 26 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 19 | Malignant Thyroid Gland NeoplasmCancer | 533 | — | observed | #19 of 26 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 20 | Malignant Salivary Gland NeoplasmCancer | 437 | — | observed | #20 of 26 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 21 | Malignant Nasopharyngeal NeoplasmCancer | 405 | — | observed | #21 of 26 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 22 | Malignant Breast NeoplasmCancer Family | 379 | — | observed | #22 of 26 | USCS "Male Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 23 | Malignant Testicular NeoplasmCancer | 344 | — | observed | #23 of 26 | USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629) | cdc-uscsObserved |
| 24 | Malignant Hypopharyngeal NeoplasmCancer | 251 | — | observed | #24 of 26 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 25 | Malignant Penile NeoplasmCancer | 250 | — | observed | #25 of 26 | USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609) | cdc-uscsObserved |
| 26 | Malignant Anal NeoplasmCancer | 186 | — | observed | #26 of 26 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By new cases
2003 · Male · all ages · 27 site groups
| # | Cancer | New cases (count) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Prostate NeoplasmCancer | 205,033 | — | observed | #1 of 27 | USCS "Prostate" (ICD-10 C61; ICD-O-3 C619) | cdc-uscsObserved |
| 2 | Malignant Lung NeoplasmCancer | 114,009 | — | observed | #2 of 27 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 3 | Malignant Colon NeoplasmCancer | 55,028 | — | observed | #3 of 27 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 4 | Malignant Bladder NeoplasmCancer | 47,592 | — | observed | #4 of 27 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 5 | Non-Hodgkin LymphomaHematologic Malignancy | 30,367 | — | observed | #5 of 27 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 6 | Cutaneous MelanomaCancer | 28,848 | — | observed | #6 of 27 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 7 | Malignant Kidney NeoplasmCancer | 25,834 | — | observed | #7 of 27 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 8 | Malignant Rectal NeoplasmCancer | 23,616 | — | observed | #8 of 27 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 9 | LeukemiaCancer Family | 22,357 | — | observed | #9 of 27 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 10 | Malignant Pancreatic NeoplasmCancer | 16,563 | — | observed | #10 of 27 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 11 | Malignant Gastric NeoplasmCancer | 12,836 | — | observed | #11 of 27 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 12 | Malignant Esophageal NeoplasmCancer | 11,369 | — | observed | #12 of 27 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 13 | Malignant Liver NeoplasmCancer | 11,327 | — | observed | #13 of 27 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 14 | Malignant Central Nervous System NeoplasmCancer | 10,881 | — | observed | #14 of 27 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 15 | Malignant Laryngeal NeoplasmCancer | 9,765 | — | observed | #15 of 27 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 16 | Multiple MyelomaHematologic Malignancy | 9,215 | — | observed | #16 of 27 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 17 | Malignant Testicular NeoplasmCancer | 7,778 | — | observed | #17 of 27 | USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629) | cdc-uscsObserved |
| 18 | Malignant Thyroid Gland NeoplasmCancer | 6,147 | — | observed | #18 of 27 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 19 | Hodgkin LymphomaHematologic Malignancy | 4,472 | — | observed | #19 of 27 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 20 | Malignant MesotheliomaCancer Family | 2,450 | — | observed | #20 of 27 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 21 | Malignant Salivary Gland NeoplasmCancer | 2,139 | — | observed | #21 of 27 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 22 | Malignant Hypopharyngeal NeoplasmCancer | 1,933 | — | observed | #22 of 27 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 23 | Malignant Anal NeoplasmCancer | 1,794 | — | observed | #23 of 27 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 24 | Malignant Breast NeoplasmCancer Family | 1,617 | — | observed | #24 of 27 | USCS "Male Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 25 | Kaposi SarcomaCancer | 1,246 | — | observed | #25 of 27 | USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site)) | cdc-uscsObserved |
| 26 | Malignant Nasopharyngeal NeoplasmCancer | 1,216 | — | observed | #26 of 27 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 27 | Malignant Penile NeoplasmCancer | 1,144 | — | observed | #27 of 27 | USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By mortality rate (age-standardized)
2003 · Male · all ages · 26 site groups · 2000 U.S. standard population (19 age groups)
| # | Cancer | Mortality rate (age-standardized) (per 100,000) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Lung NeoplasmCancer | 72 | 71.6–72.5 | observed | #1 of 26 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 2 | Malignant Prostate NeoplasmCancer | 27.2 | 26.9–27.5 | observed | #2 of 26 | USCS "Prostate" (ICD-10 C61; ICD-O-3 C619) | cdc-uscsObserved |
| 3 | Malignant Colon NeoplasmCancer | 19.4 | 19.1–19.6 | observed | #3 of 26 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 4 | Malignant Pancreatic NeoplasmCancer | 12.1 | 11.9–12.3 | observed | #4 of 26 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 5 | LeukemiaCancer Family | 10 | 9.8–10.2 | observed | #5 of 26 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 6 | Non-Hodgkin LymphomaHematologic Malignancy | 9.4 | 9.2–9.6 | observed | #6 of 26 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 7 | Malignant Esophageal NeoplasmCancer | 7.7 | 7.6–7.9 | observed | #7 of 26 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 8 | Malignant Bladder NeoplasmCancer | 7.5 | 7.3–7.7 | observed | #8 of 26 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 9 | Malignant Liver NeoplasmCancer | 7.4 | 7.2–7.5 | observed | #9 of 26 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 10 | Malignant Kidney NeoplasmCancer | 6.1 | 6–6.2 | observed | #10 of 26 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 11 | Malignant Gastric NeoplasmCancer | 5.7 | 5.6–5.9 | observed | #11 of 26 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 12 | Malignant Central Nervous System NeoplasmCancer | 5.4 | 5.2–5.5 | observed | #12 of 26 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 13 | Multiple MyelomaHematologic Malignancy | 4.6 | 4.5–4.7 | observed | #13 of 26 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 14 | Cutaneous MelanomaCancer | 3.9 | 3.8–4 | observed | #14 of 26 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 15 | Malignant Rectal NeoplasmCancer | 3.8 | 3.7–3.9 | observed | #15 of 26 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 16 | Malignant Laryngeal NeoplasmCancer | 2.4 | 2.3–2.4 | observed | #16 of 26 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 17 | Malignant MesotheliomaCancer Family | 1.7 | 1.6–1.7 | observed | #17 of 26 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 18 | Hodgkin LymphomaHematologic Malignancy | 0.6 | 0.5–0.6 | observed | #18 of 26 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 19 | Malignant Salivary Gland NeoplasmCancer | 0.4 | 0.3–0.4 | observed | #19 of 26 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 20 | Malignant Thyroid Gland NeoplasmCancer | 0.4 | 0.4–0.5 | observed | #19 of 26 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 21 | Malignant Breast NeoplasmCancer Family | 0.3 | 0.3–0.3 | observed | #21 of 26 | USCS "Male Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 22 | Malignant Nasopharyngeal NeoplasmCancer | 0.3 | 0.3–0.3 | observed | #21 of 26 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 23 | Malignant Hypopharyngeal NeoplasmCancer | 0.2 | 0.2–0.2 | observed | #23 of 26 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 24 | Malignant Penile NeoplasmCancer | 0.2 | 0.2–0.2 | observed | #23 of 26 | USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609) | cdc-uscsObserved |
| 25 | Malignant Testicular NeoplasmCancer | 0.2 | 0.2–0.3 | observed | #23 of 26 | USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629) | cdc-uscsObserved |
| 26 | Malignant Anal NeoplasmCancer | 0.1 | 0.1–0.2 | observed | #26 of 26 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Top cancers
By incidence rate (age-standardized)
2003 · Male · all ages · 27 site groups · 2000 U.S. standard population (19 age groups)
| # | Cancer | Incidence rate (age-standardized) (per 100,000) | 95% CI | Type | Rank in scope | Site definition | Source |
|---|---|---|---|---|---|---|---|
| 1 | Malignant Prostate NeoplasmCancer | 158.3 | 157.6–159 | observed | #1 of 27 | USCS "Prostate" (ICD-10 C61; ICD-O-3 C619) | cdc-uscsObserved |
| 2 | Malignant Lung NeoplasmCancer | 89.8 | 89.3–90.3 | observed | #2 of 27 | USCS "Lung and Bronchus" (ICD-10 C34; ICD-O-3 C340-C349) | cdc-uscsObserved |
| 3 | Malignant Colon NeoplasmCancer | 44.2 | 43.8–44.6 | observed | #3 of 27 | USCS "Colon excluding Rectum" (ICD-10 C18, C26.0; ICD-O-3 C180-C189, C260) | cdc-uscsObserved |
| 4 | Malignant Bladder NeoplasmCancer | 38.7 | 38.4–39.1 | observed | #4 of 27 | USCS "Urinary Bladder" (ICD-10 C67; ICD-O-3 C670-C679) | cdc-uscsObserved |
| 5 | Non-Hodgkin LymphomaHematologic Malignancy | 23.5 | 23.2–23.7 | observed | #5 of 27 | USCS "Non-Hodgkin Lymphoma" (ICD-10 C82-C85, C96.3; ICD-O-3 histology 9590-9597, 9670-9729, 9735, 9737-9738 (+9811-9818, 9823, 9827, 9837 outside marrow/blood)) | cdc-uscsObserved |
| 6 | Cutaneous MelanomaCancer | 22 | 21.7–22.2 | observed | #6 of 27 | USCS "Melanomas of the Skin" (ICD-10 C43; ICD-O-3 C440-C449 with histology 8720-8790) | cdc-uscsObserved |
| 7 | Malignant Kidney NeoplasmCancer | 19.5 | 19.3–19.8 | observed | #7 of 27 | USCS "Kidney and Renal Pelvis" (ICD-10 C64-C65; ICD-O-3 C649, C659) | cdc-uscsObserved |
| 8 | Malignant Rectal NeoplasmCancer | 18.2 | 17.9–18.4 | observed | #8 of 27 | USCS "Rectum and Rectosigmoid Junction" (ICD-10 C19-C20; ICD-O-3 C199, C209) | cdc-uscsObserved |
| 9 | LeukemiaCancer Family | 17.5 | 17.3–17.8 | observed | #9 of 27 | USCS "Leukemias" (ICD-10 C91-C95 (leukemia recodes; C90.1 plasma cell leukemia included by SEER); ICD-O-3 leukemia histologies 9733-9948 per SEER site recode) | cdc-uscsObserved |
| 10 | Malignant Pancreatic NeoplasmCancer | 13.1 | 12.9–13.3 | observed | #10 of 27 | USCS "Pancreas" (ICD-10 C25; ICD-O-3 C250-C259) | cdc-uscsObserved |
| 11 | Malignant Gastric NeoplasmCancer | 10.2 | 10–10.4 | observed | #11 of 27 | USCS "Stomach" (ICD-10 C16; ICD-O-3 C160-C169) | cdc-uscsObserved |
| 12 | Malignant Esophageal NeoplasmCancer | 8.7 | 8.6–8.9 | observed | #12 of 27 | USCS "Esophagus" (ICD-10 C15; ICD-O-3 C150-C159) | cdc-uscsObserved |
| 13 | Malignant Liver NeoplasmCancer | 8.5 | 8.4–8.7 | observed | #13 of 27 | USCS "Liver and Intrahepatic Bile Duct" (ICD-10 C22; ICD-O-3 C220-C221) | cdc-uscsObserved |
| 14 | Malignant Central Nervous System NeoplasmCancer | 8 | 7.9–8.2 | observed | #14 of 27 | USCS "Brain and Other Nervous System" (ICD-10 C70, C71, C72; ICD-O-3 C700-C709, C710-C719, C720-C729) | cdc-uscsObserved |
| 15 | Malignant Laryngeal NeoplasmCancer | 7.3 | 7.2–7.5 | observed | #15 of 27 | USCS "Larynx" (ICD-10 C32; ICD-O-3 C320-C329) | cdc-uscsObserved |
| 16 | Multiple MyelomaHematologic Malignancy | 7.3 | 7.1–7.4 | observed | #15 of 27 | USCS "Myeloma" (ICD-10 C90.0, C90.2; ICD-O-3 histology 9731-9732, 9734) | cdc-uscsObserved |
| 17 | Malignant Testicular NeoplasmCancer | 5.4 | 5.3–5.5 | observed | #17 of 27 | USCS "Testis" (ICD-10 C62; ICD-O-3 C620-C629) | cdc-uscsObserved |
| 18 | Malignant Thyroid Gland NeoplasmCancer | 4.4 | 4.3–4.5 | observed | #18 of 27 | USCS "Thyroid" (ICD-10 C73; ICD-O-3 C739) | cdc-uscsObserved |
| 19 | Hodgkin LymphomaHematologic Malignancy | 3.2 | 3.1–3.3 | observed | #19 of 27 | USCS "Hodgkin Lymphoma" (ICD-10 C81; ICD-O-3 histology 9650-9667 (nodal and extranodal)) | cdc-uscsObserved |
| 20 | Malignant MesotheliomaCancer Family | 2 | 1.9–2.1 | observed | #20 of 27 | USCS "Mesothelioma" (ICD-10 C45; ICD-O-3 histology 9050-9055 (any site)) | cdc-uscsObserved |
| 21 | Malignant Salivary Gland NeoplasmCancer | 1.7 | 1.6–1.8 | observed | #21 of 27 | USCS "Salivary Gland" (ICD-10 C07-C08; ICD-O-3 C079-C089) | cdc-uscsObserved |
| 22 | Malignant Hypopharyngeal NeoplasmCancer | 1.4 | 1.4–1.5 | observed | #22 of 27 | USCS "Hypopharynx" (ICD-10 C12-C13; ICD-O-3 C129, C130-C139) | cdc-uscsObserved |
| 23 | Malignant Anal NeoplasmCancer | 1.3 | 1.3–1.4 | observed | #23 of 27 | USCS "Anus, Anal Canal and Anorectum" (ICD-10 C21; ICD-O-3 C210-C212, C218) | cdc-uscsObserved |
| 24 | Malignant Breast NeoplasmCancer Family | 1.3 | 1.2–1.3 | observed | #23 of 27 | USCS "Male Breast" (ICD-10 C50; ICD-O-3 C500-C509) | cdc-uscsObserved |
| 25 | Kaposi SarcomaCancer | 0.9 | 0.9–1 | observed | #25 of 27 | USCS "Kaposi Sarcoma" (ICD-10 C46; ICD-O-3 histology 9140 (any site)) | cdc-uscsObserved |
| 26 | Malignant Nasopharyngeal NeoplasmCancer | 0.9 | 0.8–0.9 | observed | #25 of 27 | USCS "Nasopharynx" (ICD-10 C11; ICD-O-3 C110-C119) | cdc-uscsObserved |
| 27 | Malignant Penile NeoplasmCancer | 0.9 | 0.8–1 | observed | #25 of 27 | USCS "Penis" (ICD-10 C60; ICD-O-3 C600-C609) | cdc-uscsObserved |
cdc-uscsProvenance
- Source
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortality
- Dataset
- U.S. Cancer Statistics — Data Visualizations tool data tables (BYSITE.TXT)
- Version
- USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- registry
- License
- US Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- Run
- ING-CDCUSCS-20260908-000001
Data updated 22 days agoSource updated USCS 1999-2023 ASCII package, Nov 2025 submission (last-modified Thu, 04 Jun 2026 20:40:00 GMT; sha256 291765c997e5)
Trend
Mortality rate (age-standardized) — top 8 cancers, all years
Top cancers of 2003 (Male) traced over every year published for United States. Dashed lines mark estimated or projected values; the y axis starts at zero.
cdc-uscsObservedstandard: 2000 U.S. standard population (19 age groups)264 points
Clinical research
Clinical trial activity in United States
Registrant-entered study locations on ClinicalTrials.gov mapped to this country (any study type, any phase). A site is one location; a multi-site study weighs by its number of sites. Recruiting = location status RECRUITING, or the study status when the site has none.
- Sites
- 609,751
- Studies with a site here
- 50,884
- Recruiting sites
- 71,552
- Recruiting studies
- 7,740
Computed formula ci-trial-sites-v1 · source: clinicaltrials · shares are of sites, not of studies
Data updated 16 hours agoSource updated unknowntrial_site_country_counts
Regulatory
Oncology approval records · US
Records of the country's regulator as ingested (one record = one decision for one application or product identifier). Absence of a record here is not evidence of absence.
FDA · approved: 2,343 records / 304 drugs
- Sep 18, 2026Abemaciclib approved cancer not stated in this recordEfficacy supplement 2026-09-18 (see label)openfda
- Sep 9, 2026Aminolevulinic Acid approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
- Sep 9, 2026Sevabertinib approved cancer not stated in this recordEfficacy supplement 2026-09-09 (see label)openfda
- Sep 4, 2026Camizestrant approved Malignant Breast Neoplasmin combination with a CDK4/6 inhibitor (abemaciclib, palbociclib, or ribociclib) for the treatment of adult patients with hormone receptor…openfda
- Aug 28, 2026Ropeginterferon Alfa-2b approved cancer not stated in this recordEfficacy supplement 2026-08-28 (see label)openfda
- Aug 25, 2026Zanidatamab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
- Aug 25, 2026Tislelizumab approved cancer not stated in this recordEfficacy supplement 2026-08-25 (see label)openfda
- Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
- Jul 24, 2026Enzalutamide approved cancer not stated in this recordEfficacy supplement 2026-07-24 (see label)openfda
- Jul 14, 2026Selpercatinib approved cancer not stated in this recordEfficacy supplement 2026-07-14 (see label)openfda
Regulatory
Provenance
Sources and freshness
What each source covers for this geography, exactly as ingested. Values are normalized (units, labels) but never changed.
| Source | Metric | Sex | Years | Cancers | Estimate types | Standard population | Ingested |
|---|---|---|---|---|---|---|---|
| cdc-uscs | Incidence rate (age-standardized) | Both | 1999–2023 (25) | 24 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Incidence rate (age-standardized) | Female | 1999–2023 (25) | 29 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Incidence rate (age-standardized) | Male | 1999–2023 (25) | 27 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Both | 1999–2024 (26) | 23 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Both | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Female | 1999–2024 (26) | 28 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Female | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | Mortality rate (age-standardized) | Male | 1999–2024 (26) | 26 | observed | 2000 U.S. standard population (19 age groups) | 2026-09-08 |
| cdc-wonder | Mortality rate (age-standardized) | Male | 2018–2024 (7) | 36 | observed | 2000 U.S. Std. Population | 2026-09-08 |
| cdc-uscs | New cases | Both | 1999–2023 (25) | 32 | observed | — | 2026-09-08 |
| cdc-uscs | New cases | Female | 1999–2023 (25) | 29 | observed | — | 2026-09-08 |
| cdc-uscs | New cases | Male | 1999–2023 (25) | 27 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Both | 1999–2024 (26) | 31 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Both | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Female | 1999–2024 (26) | 28 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Female | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-uscs | Deaths | Male | 1999–2024 (26) | 26 | observed | — | 2026-09-08 |
| cdc-wonder | Deaths | Male | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Both | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Female | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
| cdc-wonder | Mortality rate (crude) | Male | 2018–2024 (7) | 36 | observed | — | 2026-09-08 |
- U.S. Cancer Statistics (USCS) — NPCR/SEER incidence and NVSS mortalitylicense: approvedUS Government work (public domain); citation requested; statistical reporting and analysis only; no linkage for re-identification
- CDC WONDER — Underlying Cause of Death (US mortality by ICD-10 site)license: approvedUS Government work (public domain) subject to CDC WONDER data use restrictions (statistical reporting only; counts ≤ 9 must not be published; no re-identification)
Age-standardized rates use the 2000 U.S. standard population (19 age groups); they are not comparable with rates standardized to the World (Segi) population used by IARC. Global comparisons are not available: the IARC Global Cancer Observatory remains under license review and the SEER API awaits credentials (CLAUDE.md §10.3-10.4). Only geographies with licensed observations get a page; see /countries.
Data updated 22 days agoSource updated 1999–202410,680 observations approx. · ranks from snapshots geo=USA